- Home
- OPTN vs IMMX Comparison
OPTN vs IMMX Comparison
Compare OPTN & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPTN
- IMMX
- Stock Information
- Founded
- OPTN 2010
- IMMX 2014
- Country
- OPTN United States
- IMMX United States
- Employees
- OPTN N/A
- IMMX N/A
- Industry
- OPTN Biotechnology: Pharmaceutical Preparations
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- OPTN Health Care
- IMMX Health Care
- Exchange
- OPTN Nasdaq
- IMMX Nasdaq
- Market Cap
- OPTN 55.4M
- IMMX 50.1M
- IPO Year
- OPTN 2017
- IMMX 2021
- Fundamental
- Price
- OPTN $9.17
- IMMX $1.64
- Analyst Decision
- OPTN Hold
- IMMX Strong Buy
- Analyst Count
- OPTN 3
- IMMX 1
- Target Price
- OPTN $9.00
- IMMX $7.00
- AVG Volume (30 Days)
- OPTN 141.6K
- IMMX 41.7K
- Earning Date
- OPTN 05-13-2025
- IMMX 05-08-2025
- Dividend Yield
- OPTN N/A
- IMMX N/A
- EPS Growth
- OPTN N/A
- IMMX N/A
- EPS
- OPTN N/A
- IMMX N/A
- Revenue
- OPTN $78,226,000.00
- IMMX N/A
- Revenue This Year
- OPTN $30.49
- IMMX N/A
- Revenue Next Year
- OPTN $13.51
- IMMX N/A
- P/E Ratio
- OPTN N/A
- IMMX N/A
- Revenue Growth
- OPTN 10.20
- IMMX N/A
- 52 Week Low
- OPTN $4.82
- IMMX $1.26
- 52 Week High
- OPTN $20.03
- IMMX $2.73
- Technical
- Relative Strength Index (RSI)
- OPTN 76.77
- IMMX 49.75
- Support Level
- OPTN $8.75
- IMMX $1.57
- Resistance Level
- OPTN $9.28
- IMMX $1.57
- Average True Range (ATR)
- OPTN 0.14
- IMMX 0.18
- MACD
- OPTN -0.11
- IMMX 0.01
- Stochastic Oscillator
- OPTN 79.25
- IMMX 73.17
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.